Bioasis Announces Investor Relations Service Agreement with Stern IR

GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has engaged Stern Investor Relations, Inc. (“Stern IR”) to provide strategic advisory services, enhance and execute the Company’s investor relations program and support ongoing efforts to expand visibility within the North American investment community in compliance with regulatory guidelines.

“In an increasingly complex and diverse marketplace, an effective investor relations program is essential to communicate our growth strategy, differentiate Bioasis in the eyes of investors and position our company for long-term success,” said Catherine London, executive vice president, investor relations and corporate communications, Bioasis. “The Stern IR team of investor relations professionals has a proven track record of success in connecting biotech companies with the broader investment community. We look forward to working with them to expand our company visibility among prospective investors in the months ahead.”

Under the terms of the agreement, Stern IR will provide comprehensive investor relations services for an initial six-month term, commencing Oct. 4, 2018, at an anticipated cost of $90,000, payable at the rate of $15,000 per month. The agreement is subject to acceptance by the TSX Venture Exchange.

“There are many therapies that have the potential to make a world of difference in the treatment of CNS diseases, but too many of them cannot be delivered at therapeutic levels to their targets in the brain. We are very energized by the potential that our xB3 platform technology has shown to deliver many of these treatments across the BBB for the treatment of brain cancers and other neurological disorders. The safe delivery of treatments to the brain could be game changers for those afflicted with neurological disorders,” said Mark Day, Ph.D., director, president and chief executive officer, Bioasis. “We look forward to the Stern IR team helping us raise investor and industry awareness of Bioasis and our technology.”

On behalf of the Board of Directors of Bioasis Technologies Inc. 
Mark Day, Ph.D., Director and President & Chief Executive Officer

Read full news release here.